Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: SRPT sarepta.com
Sarepta Therapeutics is a biotechnology company focused on precision genetic medicine for rare diseases, with a particular emphasis on Duchenne muscular dystrophy (DMD). The company commercializes four approved therapies: three PMO exon-skipping treatments (EXONDYS 51, VYONDYS 53, and AMONDYS 45) that target different exon mutations in the dystrophin gene, and ELEVIDYS, an AAV-based gene transfer therapy for ambulatory DMD patients aged 4 and older. Sarepta generates revenue from direct U.S. product sales, collaboration revenues from its partnership with Roche for ex-U.S. ELEVIDYS commercialization (including contract manufacturing and milestone payments), and licensing arrangements. The company is expanding beyond DMD with an siRNA pipeline targeting myotonic dystrophy type 1 (DM1), facioscapulohumeral dystrophy (FSHD), and Huntington's disease through its collaboration with Arrowhead Pharmaceuticals. Sarepta utilizes proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry for its exon-skipping portfolio and is developing next-generation genetic medicine approaches across muscle, central nervous system, and cardiac diseases. Updated
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally…
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates…
The fear gauge pulled back on Wednesday. The CBOE Volatility Index, better known as the VIX, is trading near 25.6 this morning, a drop of roughly 5% from Tuesday’s close of 26.95,…
Sarepta Therapeutics (NASDAQ:SRPT | SRPT Price Prediction) stock is up approximately 20% in early trading on Wednesday after the company released its first-ever clinical data from two siRNA programs targeting rare neuromuscular…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
An NFL team owner continues to boost a stake in an energy stock. Insiders made notable purchases in tech and health care stocks last week as well.
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Exxon Mobil and another energy giant saw huge insider buys this week, while Bill Ackman continued to build his stake in Howard Hughes.
Monday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Accenture, Clorox, Fiserv, Moderna, Planet Fitness, Sarepta Therapeutics, Tesla, Under Armour, Ventas, Viatris, Wayfair and Welltower.
Tuesday's top analyst upgrades and downgrades included Broadcom, Caterpillar, CVS Health, Guardant Health, Marvell Technology, Nutrien, Paramount Global, RingCentral, SoFi Technologies, UnitedHealth Group and Workday.
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's, Microsoft, PulteGroup and Tesla.
Wednesday's top analyst upgrades and downgrades included American Express, Analog Devices, Boeing, Chevron, Chipotle Mexican Grill, Comcast, CSX, Etsy, Fastenal, ONEOK, Prudential Financial, RH and ServiceNow.
Monday's top analyst upgrades and downgrades included Alphabet, Bill, Bumble, Dollar General, FedEx, FMC, Jabil Circuit, Microsoft, Nike, Nvidia, Sarepta Therapeutics, Shopify, Synchrony Financial, Warner Bros. Discovery and Zscaler.
Sarepta Therapeutics is a biotechnology company focused on precision genetic medicine for rare diseases, with a particular emphasis on Duchenne muscular dystrophy (DMD).
24/7 Wall St.'s 12-month price target for SRPT is $24.10, rated Buy. The Wall Street consensus target is $21.73. SRPT price prediction →
